Towards treatments for VEXAS.
Towards treatments for VEXAS.
复制标题
针对 VEXAS 的治疗。
DOI：
10.1111/bjh.17930
复制
发表时间：
2022
影响因子：
6.5
通讯作者：
Young,NealS
中科院分区：
文献类型：
--
作者：
Patel,BhavishaA;Young,NealS
VEXAS在临床表现上是一种异质性疾病，具有多器官受累和可变的骨髓功能障碍：对治疗的反应需要在器官系统中仔细分类。虽然该队列中所有接受氮杂胞苷治疗的患者均符合基于WHO 2016的MDS标准，但治疗适应症为不受控制的炎症，尽管在8/11例病例中接受了长期皮质类固醇治疗。VEXAS是一种新的血液病。英国血液学杂志的版权是Wiley-Blackwell的财产，未经版权保持器的明确书面许可，其内容不得复制或通过电子邮件发送到多个网站或发布到列表服务器。但是，用户可以打印，下载或电子邮件的文章供个人使用。这篇摘要可以删节。不保证副本的准确性。用户应参考原始出版版本的材料的完整摘要。版权适用于所有摘要。
VEXAS is a heterogenous disease in its clinical manifestations, with multi-organ involvement and variable marrow dysfunction: responses to therapy will need to be carefully categorized across organ systems. While all included patients treated with azacytidine in this cohort met the criteria for MDS based on WHO 2016, the indication for treatment was uncontrolled inflammation despite chronic corticosteroid therapy in 8/11 cases. VEXAS is a new hematologic disease.[Extracted from the article]Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.